Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan Medoxomil in Mild to Moderate Essential Hypertension (Chinese Patients, ABPM Sub-study)
jRCT1080221127Phase 4
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of olmesartan in essential hypertension, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Efficacy of olmesartan on seated blood pressure over 24 weeks and Safety of olmesartan over 24 weeks.
02
Drugs
olmesartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT1080221127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221127.